Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo.
Cancer communications (London, England)(2018)
摘要
Our results present preclinical evidence for targeting the selective hypoxic portion of NPC by evofosfamide as a single agent and combined with DDP and provide rationale for the potential clinical application of evofosfamide for the treatment of nasopharyngeal carcinoma.
更多查看译文
关键词
Chemotherapy,Hypoxia-activated prodrug,Hypoxia-induced factor-1α (HIF-1α),Nasopharyngeal carcinoma (NPC),Xenograft tumor models
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络